ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Caribou Biosciences (CRBU) pipeline and stated timing

Pipeline at a glance

ProgramEventStageStated timingFiling
CB-011/data readoutPhase 1second half of 20268-K ·
CB-011Topline/data readoutPhase 1second half of 20268-K ·

Source: ORION, orionbiotechai.com/company/CRBU, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/CRBU

Nearest upcoming stated timing: CB-011 · Topline/data readout · second half of 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

Topline/data readoutsecond half of 2026

Stage: Phase 1SEC filing · “phase 1”

Public float: $112,500,000 · as of · SEC filing

In the second half of 2026, Caribou expects to report initial safety and efficacy from dose expansion on more than 15 patients with a minimum of three months follow up, as well as longer follow-up data on the 12-patient, BCMA-naïve RDE cohort from dose escalation.

8-K · Filed · Last checked

Source details

Accession 0001619856-26-000053

Topline/data readoutsecond half of 2026

Stage: Phase 1SEC filing · “phase 1”

Public float: $112,500,000 · as of · SEC filing

In the second half of 2026, Caribou expects to report initial safety and efficacy from dose expansion on more than 15 patients with a minimum of three months follow up

8-K · Filed · Last checked

Source details

Accession 0001619856-26-000053

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
CB-011Clinical resultssecond half of 2026
“In the second half of 2026, Caribou expects to report initial safety and efficacy from dose expansion on more than 15 patients with a minimum of three months follow up, as well as longer follow-up data on the 12-patient, BCMA-naïve RDE cohort from dose escalation.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

CB-011Clinical resultssecond half of 2026
“In the second half of 2026, Caribou expects to report initial safety and efficacy from dose expansion on more than 15 patients with a minimum of three months follow up”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch CRBU

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for CRBU. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See CRBU in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.